(489 days)
The ClearPath DS-120® Lens Fluorescence Biomicroscope is indicated for use to detect autofluorescence of the crystalline lens.
The major functional components of the ClearPath DS-120® Lens Fluorescence Biomicroscope are an optics unit and a laptop personal computer. The only components that contact the patient are a manually adjustable headrest (in/out) and a motorized adjustable chin rest (up/down). The adjustable optics window does not contact the patient.
Acceptance Criteria and Study Details for ClearPath DS-120® Lens Fluorescence Biomicroscope
1. Table of Acceptance Criteria and Reported Device Performance
The provided document describes a clinical precision study designed to evaluate the repeatability and reproducibility of the ClearPath DS-120® Lens Fluorescence Biomicroscope. The study's purpose was to characterize the variability of measurements, not to establish diagnostic or prognostic utility, and thus does not explicitly state acceptance criteria in terms of diagnostic performance metrics like sensitivity, specificity, or accuracy.
Instead, the acceptance criteria implicitly relate to the variability of measurements (repeatability and reproducibility), which indicates the device's consistency and reliability as a measurement tool. The "fitness for purpose as a measurement tool" suggests that the variability should be within an acceptable range for clinical use in detecting lens autofluorescence.
Based on the "RESULTS" and "SUDY CONCLUSION" sections, the device is deemed to meet its purpose if its repeatability and reproducibility (expressed as standard deviation (SD) and Coefficient of Variation (%CV)) are within acceptable limits for a clinical measurement tool. The study did not define specific numerical thresholds for these values as "acceptance criteria" but rather presented them as characterizations of the device's performance.
| Metric | Acceptance Criteria (Implicit) | Reported Device Performance (All Devices Combined) |
|---|---|---|
| Repeatability SD | Acceptable level for a clinical measurement tool (not explicitly quantified, but demonstrated as "fit for purpose") | 0.01034 |
| Repeatability %CV | Acceptable level for a clinical measurement tool (not explicitly quantified, but demonstrated as "fit for purpose") | 5.779% |
| Reproducibility SD | Acceptable level for a clinical measurement tool (not explicitly quantified, but demonstrated as "fit for purpose") | 0.01153 |
| Reproducibility %CV | Acceptable level for a clinical measurement tool (not explicitly quantified, but demonstrated as "fit for purpose") | 6.443% |
| Safety (Adverse Events) | No adverse events observed | No adverse events were observed |
2. Sample Size Used for the Test Set and Data Provenance
- Sample Size (Test Set): 27 participants.
- Data Provenance: Prospective, single-site study in humans. The country of origin of the data is not explicitly stated, but the submission is to the FDA (USA), implying the study was likely conducted in the USA.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts
The study was a precision study evaluating the repeatability and reproducibility of the device's measurements of lens autofluorescence. It was not designed to establish diagnostic or prognostic utility, and therefore, it did not use expert-established ground truth in the typical sense (e.g., for disease diagnosis). The "ground truth" for this study was the measurement itself as performed by the device under different conditions, which was then analyzed for variability.
4. Adjudication Method for the Test Set
Not applicable. As this was a precision study evaluating direct measurements from the device, rather than diagnostic classifications requiring expert interpretation and adjudication, no adjudication method was used. The study involved multiple operators and devices taking measurements, and the variability across these measurements was analyzed.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was Done
No, an MRMC comparative effectiveness study was not explicitly stated or performed. The study described is a precision study focused on the device's measurement consistency. It investigated inter-operator and inter-device variability but did not compare human reader performance with and without AI assistance, nor did it measure an effect size for human improvement with AI.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was Done
The ClearPath DS-120® is a measurement device that computes the ratio of lens autofluorescence to scattered light. The "summary of protocol" describes operators taking measurements, implying human interaction is part of its intended use. The study evaluates the device's performance as used by operators, rather than a standalone algorithm performance without any human interaction. The device performs automatic tracking and computation, but human operators position the patient and initiate scans. Therefore, a purely standalone algorithm evaluation was not the focus.
7. The Type of Ground Truth Used
The "ground truth" for this precision study was the repeated measurements of lens autofluorescence and scattering response in human crystalline lenses themselves. The study aimed to characterize the natural variability of these measurements taken under controlled conditions, not to correlate them with an independent "true" clinical state (like the presence or absence of a disease).
8. The Sample Size for the Training Set
The document describes a clinical precision study rather than a study involving machine learning model training. Therefore, there is no mention of a training set in the context of an algorithm or model development. The data collected was for evaluating the device's precision, not for training it.
9. How the Ground Truth for the Training Set Was Established
Not applicable, as there was no training set mentioned for machine learning model development.
{0}------------------------------------------------
JAN 3 1 2013
510(K) SUMMARY OF SAFETY AND EFFECTIVENESS
This 510(k) summary of safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
SUMMARY PREPARED: January 25, 2013
1.1 SUBMITTER'S NAME, ADDRESS, TELEPHONE NUMBER, CONTACT PERSON, AND DATE SUMMARY PREPARED
APPLICANT: Freedom Meditech, Inc. 10455 Pacific Center Court San Diego, CA 92121, USA Tel: (858)-638-1433
Contact Person: Craig H. Misrach Chairman & CEO
1.2 NAME OF DEVICE, INCLUDING TRADE NAME AND CLASSIFICATION NAME
ClearPath DS-120® Lens Fluorescence Biomicroscope TRADE NAME:
ClearPath DS-120® Lens Fluorescence Biomicroscope COMMON NAME:
CLASSIFICATION
NAME: Ophthalmoscope (Class II)
DEVICE
CLASSIFICATION: 21 CFR 886.1570
PRODUCT CODE: MYC
PREDICATE
DEVICE: Optos PIC P200MAAF Ophthalmoscope, K102492
SUBSTANTIALLY EQUIVALENT TO 1.3
| 510(K) NUMBER | TRADE OR PROPRIETARY ORMODEL NAME | MANUFACTURER |
|---|---|---|
| K102492 | PIC P200MAAFOPHTHALMOSCOPE | OPTOS |
{1}------------------------------------------------
1.4 DESCRIPTION OF THE DEVICE SUBJECT TO PREMARKET NOTIFICATION
1.4.1 MAJOR COMPONENTS
The major functional components of the ClearPath DS-120® Lens Fluorescence Biomicroscope are an optics unit and a laptop personal computer.
The only components that contact the patient are a manually adjustable headrest (in/out) and a motorized adjustable chin rest (up/down).
The adjustable optics window does not contact the patient.
1.4.2 PRINCIPLES OF OPERATION
The patient is positioned with the forehead centered on the headrest. The eye is illuminated by near-infrared lights and observed by an IR sensitive video camera. An image of the eye is displayed on the computer screen to assist the operator in the alignment of the patient's eve.
The headrest is adjusted manually so that the eye is in the camera image that is visible on the computer screen. The patient is instructed to look at a red blinking fixation light. The operator can adjust the chin rest and optics window positions to enable the patient to sit comfortably with the fixation target properly positioned. The software includes an automatic tracking program for positioning the pupil.
The blue light source and the collection optics are confocally aligned within a volume of measurement that is scanned through the lens. In the eye, this blue light is scattered by elastic (Rayleigh scattering) and inelastic (fluorescent) interactions with lens proteins. Filters in the collection optics reject light from the positioning lights and isolate blue and green light signals, which are detected by a highly sensitive photomultiplier and sent to an A/D converter and then to the computer.
Under software control, the volume of measurement is scanned through the lens and back. Computer software records both scattered and fluorescent light and computes the average of the ratio of lens autofluorescence to scattered light in the central portion of the lens. Software rejects scans that are outside of physiological limits or have anomalies due to eye blinks, or to excessive differences between the forward and reverse scans. For valid scans, the fluorescence ratio is reported on the screen and can be printed for the patient and/or for the patient's file.
1.4.3 MAINTENANCE AND CALIBRATION
There are no user serviceable parts or adjustments in the optics unit. The system self-tests when it is turned on. There is no maintenance required from the clinician other than cleaning the head and chin rest and optics window, as described in the Instruction for Use.
{2}------------------------------------------------
KI12880
1.5 INDICATION FOR USE
The ClearPath DS-120® Lens Fluorescence Biomicroscope is indicated for use to detect autofluorescence of the crystalline lens.
1.6 PREDICATE DEVICE COMPARISON TABLE
| ClearPath DS-120® LensFluorescence Biomicroscope | P200MAAF Ophthalmoscope(K102492) | |
|---|---|---|
| 1. Intended Use | To examine the eye via detectionof autofluorescence from ocularstructures | To examine the eye via detectionof autofluorescence from ocularstructures |
| 2. Indicationsfor Use | The ClearPath DS-120® LensFluorescence Biomicroscope isindicated for use to detectautofluorescence of the crystallinelens. | The P200MAAF scanning laserophthalmoscope is intended to beused as a wide field and retinalfluorescence and autofluorescenceimaging ophthalmoscope to aid inthe diagnosis and monitoring ofdiseases or disorders that manifestin the retina. |
| ClearPath DS-120® LensFluorescence Biomicroscope | P200MAAF Ophthalmoscope(K102492) | ||
|---|---|---|---|
| 3. Method ofoperation | The instrument consists of anoptoelectronic unit and acomputerized system of dataacquisition and processing. | The instrument consists of anoptoelectronic unit and acomputerized system of dataacquisition and processing. | |
| The instrument is a scanningbiomicroscope that uses a lowpower blue LED beam to scan inone dimension (depth) over thelens. | The P200MAAF is a conventionalscanning laser ophthalmoscopethat uses low power blue, red andgreen laser beams to scan in twodimensions over the retina. | ||
| The returned light is detected andused to generate a digital imagewith a computer or electronicimaging device. | The reflected (or returned) light isdetected and used to generate adigital image with a computer orelectronic imaging device. | ||
| ClearPath DS-120® LensFluorescence Biomicroscope | P200MAAF Ophthalmoscope(K102492) | ||
| The device uses a blue LED as alight source that is scanned by adeflection system in one axis(depth) to generate a one-dimensional image. | The device uses blue, green, andred lasers as light sources that arescanned by a deflection system intwo axes across the retina togenerate an image. | ||
| The scanning of the beams on oneaxis is done by a stepper motordriven displacement of a volumeof measurement at the intersectionof focused illumination andcollection optics. | The scanning of the beams on thetwo axes is done using a rotatingpolygon for the fast vertical scanand a motor driven mirror for theslower horizontal scan. | ||
| The generation of the image isperformed using light detectors,the output of which is digitized,and the data collected in acomputer for reconstruction,display, and storage. | The generation of the image isperformed using light detectors,the output of which is digitized,and the data collected in acomputer for reconstruction,display, and storage. | ||
| An alignment system helps ensurethat the patient's eye is correctlypositioned. | An alignment pattern helps ensurethat the patient's eye is correctlypositioned. | ||
| The returned light then travelsback through the device to arotating filter wheel and a discretedetector that converts the light toan electrical signal (effectively ablue and green channel). | The returned light then travelsback through the device to anarray of discrete detectors thatconverts the light to an electricalsignal (red, green and bluechannels). | ||
| This electrical signal is digitizedand used to build up an electronicpicture in a computer anddisplayed on a computer display. | This electrical signal is digitizedand used to build up an electronicpicture in a computer anddisplayed either on a cathode raytube or a liquid crystal display. | ||
| The signal strength varies as thebeam is scanned through the lens,allowing an image to be createdand recorded, revealing thevariation in its constituent materialand structures. | The signal strength varies as thelaser beam is scanned across theeye, allowing an image to becreated and recorded, revealing thevariation in its constituent materialand structures. | ||
| 4. | Exposure parameters | ClearPath DS-120® Lens Fluorescence Biomicroscope | P200MAAF Ophthalmoscope (K102492) |
| Illumination is provided by a blue LED and filter, three 880 nm LEDs, and a red fixation target. | Illumination is provided by red and blue lasers. | ||
| Compliance to electrical safety (including EMC), light emitting products, programmable devices and biocompatibility standards are met. | Compliance to electrical safety (including EMC), light emitting products, programmable devices and biocompatibility standards are met. | ||
| 5. | Data Collection and Display | Image analysis software is integrated with the data collection software. | The images can be exported from the device as "tiff" image files for analysis on a personal computer. |
| The images produced are displayed as separate blue channel and green channel images. The green channel image shows the natural fluorescence (autofluorescence) of the lens of the eye. | The images produced can be displayed as separate green channel and a red channel images. In one imaging mode, the eye is illuminated using the green laser, and a red channel image shows the natural fluorescence (autofluorescence) of the eye. In another mode, only the blue laser illuminates the retina and the green channel fluorescence is recorded. | ||
| Software detects the lens two images of the lens (forward and reverse scans), and integrates the blue and green signal intensities. The ratio of green and blue integrated measurements is displayed on the computer monitor. | Device software is designed to display images. The tiff files could be read by general purpose image analysis software (e.g., NIH Image), which would enable blue and green image intensities to be measured in user-selected image areas. | ||
| 6. | Flammability of Materials | The low power LEDs do not present ignition hazard. Materials are standard optical and electronic components. | Not available |
| ClearPath DS-120® LensFluorescence Biomicroscope | P200MAAF Ophthalmoscope(K102492) | ||
| 7. | Maximumtemperatureof parts of thedevice held bythe operatoror accessibleto the patient | All accessible parts operate nearambient temperature. | Not available |
| 8. | Brightnesscontrols | Brightness is controlled by theinstrument. | Not available |
{3}------------------------------------------------
よ//2880
{4}------------------------------------------------
· KII 2880
{5}------------------------------------------------
Both instruments have similar configurations and principles of operation. Light with selected wavelength ranges is focused on eye structures and the returned light is measured at selected wavelengths.
The Optos P200MAAF uses three lasers for illumination. The ClearPath DS-120 Lens Fluorescence Biomicroscope uses an eye-safe blue LED for illumination that is focused on the lens. No new safety issues are raised by this difference as both devices are within optical radiation safety limits.
Both instruments scan the illumination beam and record an image. The Optos scans in two directions on the retina surface. The ClearPath DS-120 Lens Fluorescence Biomicroscope scans in one direction through the depth of the lens to generate a depth profile (a one-dimensional image).
Optical Equivalency and Radiation Safety
Scanning laser ophthalmoscopes using Class 1 lasers are exempt from this requirement. The low power LED light source in this instrument does not raise new safety questions. Optical safety is further discussed below.
1.7 BRIEF SUMMARY OF NONCLINICAL AND CLINICAL TESTS AND RESULTS
1.7.1 BENCH
Bench testing has been performed for radiation safety and for linearity of the photodetector response.
OPTICAL RADIATION SAFETY
The patient is exposed to three optical sources. Three of the optical sources, the blue LED probe, the red blinking LED fixation light, and the three near-infrared illumination LEDs for pupil positioning, are actively used while the patient interacts with the instruments.
The ClearPath DS-120® Lens Fluorescence Biomicroscope has been independently reviewed for optical radiation hazard. The instrument operates at all wavelengths and
{6}------------------------------------------------
KI.2880
emission levels that would not produce any ocular injury - even within foreseeable misuse conditions.
DETECTOR LINEARITY
To demonstrate linear photometer response in the clinically relevant dynamic range of the signal, mixtures of coumarin (a fluorescent material) and microspheres (scattering) were prepared and dilutions of this mixture were measured by placing a cuvette with the mixtures in the optical path. The detector response vs. dilution factor was linear in both the fluorescence and scatter channels. We also compared the detector response observed in this experiment with the range of detector responses observed in our clinical study to confirm that these linear detector responses correspond to the dynamic range observed during clinical use.
1.7.2 Clinical Precision Study
SUMMARY OF PROTOCOL
A clinical study was performed to evaluate the repeatability and reproducibility of the ratio of the lens fluorescence and scattering response of human crystalline measured by the ClearPath DS-120. This was a prospective single-site study with a recruitment goal of twenty one (21) participants minimum to be enrolled based on the study eligibility criteria. Subjects who signed an informed consent form and met all the inclusion and exclusion underwent a ClearPath DS-120 examination. Three operators (A, B, and C) and three units of ClearPath DS-120 (1, 2, and 3) were included in the study.
In order to evaluate the inter-operator variability, each of three operators used Unit 1 to take three successful lens fluorescence measurements on each test subject. The three Operator/Device configurations for the inter-operator variability are A/1, B/1, and C/1, Therefore nine successful measurements were collected on each test subject for the interoperator evaluation.
In order to evaluate the inter-device variability, Operator A used each of the three ClearPath DS-120 units to take three successful lens fluorescence measurements on each test subject. The three Operator/Device configurations for the inter-device variability are A/1, A/2, and A/3. Therefore nine successful measurements were collected on each test subject for the inter-device evaluation.
The measurement order of the five configurations was randomized. Subjects were repositioned between all scans.
{7}------------------------------------------------
RESULTS
Demographics of the enrolled study population are shown in the table below. The gender of study subjects was reasonably distributed and the age of the study subjects ranged from 21 years to 68 years, with a median age of 46 years. The range of Lens Fluorescence measurements obtained from these 27 precision study subjects was 0.07 to 0.33.
| n/N | % | |
|---|---|---|
| Gender | ||
| Male | 14/27 | 51.9% |
| Female | 13/27 | 48.1% |
| Age (year) | ||
| N | 27 | |
| Mean | 43.9 | |
| SD | 14.9 | |
| Median | 46.0 | |
| Min | 21 | |
| Max | 68 | |
| 20 - 29 | 6/27 | 22.2% |
| 30 - 39 | 5/27 | 18.5% |
| 40 - 49 | 6/27 | 22.2% |
| 50 - 59 | 5/27 | 18.5% |
| 60 - 69 | 5/27 | 18.5% |
| Ethnicity | ||
| Asian/Pacific Islander | 8/27 | 29.6% |
| Caucasian | 16/27 | 59.3% |
| Hispanic | 1/27 | 3.7% |
| Multi-Race | 2/27 | 7.4% |
DEMOGRAPHIC INFORMATION
{8}------------------------------------------------
This table summarizes the precision data from each device and from all three devices combined.
| Statistics | All Devices (3) | Devices 1 | Devices 2 | Devices 3 |
|---|---|---|---|---|
| Number of Subjects | 27 | 27 | 27 | 27 |
| Number of Successful Scans | 405 | 243 | 81 | 81 |
| Mean | 0.17899 | 0.18029 | 0.17383 | 0.18025 |
| Standard Deviation | 0.04718 | 0.04669 | 0.04865 | 0.04741 |
| Repeatability SD' | 0.01034 | 0.01015 | 0.01170 | 0.01005 |
| Repeatability %CV1 | 5.779 | 5.630 | 6.731 | 5.576 |
| Reproducibility SD2 | 0.01153 | - | - | - |
| Reproducibility %CV2 | 6.443 | - | - | - |
PRECISION SUMMARY
1 Reveatability SD = Estimate of the standard deviation among measurements taken on the same eye using the same operator and device in the same testing session with repositioning. Repeatability %CV = Repeatability SD =Mean. x100.
2 Reproducibility SD = Estimate of the standard deviation among measurements taken on the same eve using different operators and devices, including repeatability. Reproducibility %CV = Reproducibility SD +Mean. ×100.
No adverse events were observed during the study.
STUDY CONCLUSION
This clinical precision study showed the device to be safe and characterized well the variability of the measurements provided by the Clear Path DS-120 device for the range of 0.07-0.33. The variability of the autofluorescence measurements provided by the ClearPath DS-120 device shows the device is fit for its purpose as a measurement tool. The purpose of this study was not to establish the diagnostic or prognostic utility of the device; therefore, these results do not imply any correlation with a specific clinical diagnosis or prognosis.
BASIS FOR DETERMINATION OF SUBSTANTIAL EQUIVALENCE: 1.8
As described in this 510(k) Summary, all testing deemed necessary was conducted on the ClearPath DS-120® Lens Fluorescence Biomicroscope to ensure that the device is safe and effective for its intended use when used in accordance with its Instructions for Use.
Minor differences between the Indications for Use statement and that of the predicate device do not alter the intended diagnostic effect or affect safety or effectiveness for the intended use.
The minor differences in technical characteristics between the ClearPath DS-120® Lens Fluorescence Biomicroscope and the predicate Optos P200MAAF ophthalmoscope do not affect safety or effectiveness for the intended use. The physics of the measurement and basic system functions are the same as the Optos P200MAAF. The descriptive rationale for substantial equivalence is supported by bench and clinical testing as described above.
{9}------------------------------------------------
Image /page/9/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a stylized depiction of a human figure embracing a globe, enclosed within a circular border. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" is arranged around the perimeter of the circle.
January 31, 2013
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-002
Freedom Meditech, Inc. % Mr. Craig H. Misrach, MBA, CPA Chairman & CEO 10455 Pacific Center Court San Diego, CA 92121
Re: K112880
Trade/Device Name: ClearPath DS-120® Lens Fluorescence Biomicroscope Regulation Number: 21 CFR 886.1570 Regulation Name: Ophthalmoscope Regulatory Class: Class II Product Code: MYC Dated: January 25, 2013 Received: January 28, 2013
Dear Mr. Misrach:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21
{10}------------------------------------------------
Page 2 - Mr. Craig H. Misrach, MBA, CPA
CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Kesia Y. Alexander -S
for Malvina B. Eydelman, M.D. Director Division of Opthalmic and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{11}------------------------------------------------
K112880 510(k) Number (if known): ____________________________________________________________________________________________________________________________________________________
ClearPath DS-120® Lens Fluorescence Biomicroscope Device Name:
Indications for Use:
The ClearPath DS-120® Lens Fluorescence Biomicroscope is indicated for use to detect autofluorescence of the crystalline lens.
Prescription Use AND/OR Over-The-Counter Use X (Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
CLC
(Division Sign-Off) Division of Ophthalmic and Ear, Nose and Throat Devices 510(k) Number_________________________________________________________________________________________________________________________________________________________________
Page 1 of 1
§ 886.1570 Ophthalmoscope.
(a)
Identification. An ophthalmoscope is an AC-powered or battery-powered device containing illumination and viewing optics intended to examine the media (cornea, aqueous, lens, and vitreous) and the retina of the eye.(b)
Classification. Class II (special controls). The device, when it is an AC-powered opthalmoscope, a battery-powered opthalmoscope, or a hand-held ophthalmoscope replacement battery, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 886.9.